Laurus Labs vs Zydus Lifesciences: share price, P/E, ROE and financials compared
Laurus Labs
Zydus Lifesciences
Laurus Labs and Zydus Lifesciences at a glance
Laurus Labs and Zydus Lifesciences are both listed in Healthcare. Laurus Labs is the larger by market cap, at ₹1.3L Cr against ₹1.2L Cr for Zydus Lifesciences. On valuation, Zydus Lifesciences has the lower P/E (28.6× against 94.4×) and the lower price-to-book (4.29× against 20.86×). On returns and margins, Laurus Labs has the higher ROE (24.0% against 14.7%) and the higher operating margin (30.4% against 26.2%). Over three years, Zydus Lifesciences has faster 3-year sales growth (+16.5% against +3.8% a year) and faster 3-year profit growth (+37.0% against +4.0% a year). Debt-to-equity is similar, 0.42× for Laurus Labs and 0.46× for Zydus Lifesciences.
Key metrics, side by side
| Metric | Laurus LabsLAURUSLABS | Zydus LifesciencesZYDUSLIFE |
|---|---|---|
| Price (₹) | 2,340.00 | 1,197.90 |
| Market cap (₹ Cr) | 1,26,433 | 1,19,491 |
| P/E | 94.4× | 28.6× (the lower figure, shaded) |
| P/B | 20.86× | 4.29× (the lower figure, shaded) |
| Dividend yield, trailing | 0.05% | 0.08% |
| ROE | 24.0% (the higher figure, shaded) | 14.7% |
| ROCE | 19.5% | 19.0% |
| Operating margin (OPM) | 30.4% (the higher figure, shaded) | 26.2% |
| Net margin (NPM) | 17.1% (the higher figure, shaded) | 13.8% |
| Sales CAGR 3Y | +3.8% | +16.5% (the higher figure, shaded) |
| Profit CAGR 3Y | +4.0% | +37.0% (the higher figure, shaded) |
| Debt to equity | 0.42× | 0.46× |
| Interest cover | 8.3× | 19.1× (the higher figure, shaded) |
| Net profit TTM (₹ Cr) | 1,340 | – |
| 1Y return | +138.6% (the higher figure, shaded) | +22.8% |
| Promoter holding | 27.47% | – |
Laurus Labs vs Zydus Lifesciences: common questions
Which is bigger, Laurus Labs or Zydus Lifesciences?
By market cap, Laurus Labs is bigger at ₹1.3L Cr, against ₹1.2L Cr for Zydus Lifesciences (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Laurus Labs or Zydus Lifesciences?
Laurus Labs trades at a P/E of 94.4× and Zydus Lifesciences at 28.6×. Zydus Lifesciences has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Laurus Labs or Zydus Lifesciences?
Laurus Labs reports a return on equity of 24.0% and Zydus Lifesciences 14.7%. Laurus Labs has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Laurus Labs or Zydus Lifesciences?
Over the last three years: Sales grew +3.8% a year at Laurus Labs and +16.5% at Zydus Lifesciences, so Zydus Lifesciences grew sales faster; profit grew +4.0% a year at Laurus Labs and +37.0% at Zydus Lifesciences, so Zydus Lifesciences grew profit faster. Past growth doesn’t predict future growth.